Freedom Capital analyst Gene Mannheimer initiated coverage of Doximity (DOCS) with a Buy rating and $31 price target The firm views Doximity as “more than just a ‘LinkedIn for docs’,” but as a sticky platform with massive network effects, above average growth potential and enormous leverage as the model scales, the analyst tells investors. The firm sees recent weakness in shares as “an opportunity to establish or increase positions,” the analyst added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target lowered to $33 from $40 at JPMorgan
- Doximity price target raised to $42 from $40 at Piper Sandler
- Down Over 30% This Year: Analysts Double Down on These 3 Beaten-Down Stocks
- Doximity upgraded to Buy from Hold at Canaccord
- Doximity: Network Effects, Normalizing Pharma Budgets, and Undemanding Valuation Create an Attractive Buy Opportunity